Analyzing Eidos Therapeutics (EIDX) & Its Rivals
Eidos Therapeutics (NASDAQ: EIDX) is one of 555 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Eidos Therapeutics to similar companies based on the strength of its risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.
Valuation & Earnings
This table compares Eidos Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Eidos Therapeutics||N/A||-$33.29 million||-14.78|
|Eidos Therapeutics Competitors||$2.14 billion||$224.95 million||-3.96|
This table compares Eidos Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eidos Therapeutics Competitors||-1,563.74%||-832.39%||-27.72%|
Institutional and Insider Ownership
30.9% of Eidos Therapeutics shares are held by institutional investors. Comparatively, 45.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of recent ratings for Eidos Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eidos Therapeutics Competitors||4757||13459||28236||1023||2.54|
Eidos Therapeutics currently has a consensus target price of $30.29, suggesting a potential upside of 10.17%. As a group, “Pharmaceutical preparations” companies have a potential upside of 61.32%. Given Eidos Therapeutics’ peers higher possible upside, analysts plainly believe Eidos Therapeutics has less favorable growth aspects than its peers.
Eidos Therapeutics peers beat Eidos Therapeutics on 7 of the 12 factors compared.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.